Table 2.
Peptide | Dose | Proliferation | IFN-γ | IL-17 | IL-10 | ||||
---|---|---|---|---|---|---|---|---|---|
(μg/ml) | Healthy | SLE | Healthy | SLE | Healthy | SLE | Healthy | SLE | |
Resting† | - | ns | ***⇩ | ns | ns | ns | ns | ns | ***⇧ |
U170K | 10 | *⇩ | **⇩ | ns | ns | ns | *⇩ | ns | **⇧ |
20 | *⇩ | *⇩ | ns | ns | ns | **⇩ | ns | ns | |
H3 | 10 | ns | ns | ns | ns | ns | *⇩ | ns | ns |
20 | ns | **⇧ | ns | ns | ns | ns | *⇩ | *⇩ | |
H4 | 10 | **⇩ | ns | ns | ns | *⇩ | ns | *⇩ | ***⇧ |
20 | ns | ns | ns | ns | ns | ns | ns | ***⇧ | |
PPD | 5 | **⇧ | ns | ***⇧ | ns | ns | ns | ns | *⇧ |
αCD3 | 5 | ns | *⇩ | ns | **⇩ | ns | *⇩ | ns | ns |
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
CD cluster of differentiation, H3, histone 3, H4 histone 4, IFN interferon, IL interleukin, ns not significant, PPD purified protein derivative, SLE systemic lupus erythematosus, U170K U1 small nuclear ribonucleoprotein 70 kDa
† = resting PBMC at day 5. Arrows next to probabilty asterix represent significant increase or decrease in test sample